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In the past decade, several model 
systems have been developed to study 
the details of the production of secre- 
tory IgA by the mucosal surface. Until 
recently, most attention in vaccine 
research has been directed toward 
establishing a vigorous systemic 
(predominantly IgG) humoral immune 
response to the infectious agent. With 
the recognition, however, that secretory 
IgA is overwhelmingly the predominant 
immunoglobulin along mucosal sur- 
faces and likely responsible for host 
defense, much work has been directed 
at understanding initiation of the secre- 
tory IgA response and to establishing a 
secretory IgA memory response. Also, 
the mechanisms by which secretory IgA 
affects protection are being sought. 
Unlike IgG, secretory IgA does not op- 
sonize for phagocytosis or efficiently 
activate complement for cell destruction 
by membrane damage. Rather, secre- 
tory IgA seems to afford protection by 
preventing attachment of microor- 
ganisms and/or their toxic product to 
the delicate surface epithelium that 
lines the mucosa. 
Antigen Processing and 
Regulatory T Cells in the Mucosal 
Immune System 
Specialized surface epithelial cells 
which overlie lymphoid follicles, 
Peyer's patches, and the appendix have 
been identified that take up both lu- 
minal macromolecules and microor- 
ganisms for antigen processing. These 
M cells can take up macromolecules 
such as horseradish peroxidase within a 
few minutes of their application to the 
intestinal lumen (12). Larger struc- 
tures, such as reovirus or Shigella flex- 
neri, are taken up more slowly, 
requiring 1 to 1.5 hr before ingestion 
can be reliably demonstrated (16). A 
potential problem with antigen pro- 
cessing in the gut, however, is that 
when invasive microorganisms such as 
Shigella flexneri or enteropathogenic 
viruses are taken up by M cells, the 
pathogens may use the M cells as sites 
for replication and further invasion. 
Indeed, in a recent editorial, Sneller 
and Strober suggested that this may be 
the route of invasion by the AIDS virus 
(15). The rectal mucosa has abundant 
isolated lymphoid follicles which con- 
tain such M cells. Preliminary work 
from our own laboratory, however, 
suggests that preexisting secretory IgA 
will prevent this M cell uptake by live, 
invasive Shigella. Therefore, with ap- 
propriate vaccination, it may be pos- 
sible to control uptake of undesirable 
microorganisms and toxic molecules by 
the gastrointestinal tract lymphoid 
tissue. 
Following uptake of antigen, the 
material is brought to the underlying 
lymphoid tissues that are enriched in 
precursor B lymphocytes for an IgA re- 
sponse. At this stage of development, 
most B lymphocytes in the gut-asso- 
ciated lymphoid tissues (GALT) ex- 
press surface IgM and/or IgD. 
Immunoregulatory T lymphocytes are 
present in GALT that influence the de- 
velopment of IgA precursor B lympho- 
cytes. These regulatory cells include 
switch T cells as described by Kawan- 
ishi and associates (6). Under the in- 
fluence of lipopolysaccharide, clones of 
these switch T cells alter the surface 
immunoglobulin expression of Peyer's 
patch B lymphocytes from IgM to 
IgA. Several other laboratories have 
described helper T cells for the IgA re- 
sponse. These cells encourage differ- 
entiation of B lymphocytes which 
already bear surface IgA, toward be- 
coming mature plasma cells (14). In 
addition to regulatory T cells, it is clear 
that the B lymphocytes within GALT 
have an inherent genetic propensity for 
becoming IgA synthesizing and se- 
creting plasma cells (2). 
Oral antigen administration also sets 
immunosuppressive events in motion. 
Following mucosal stimulation with 
particulate or soluble antigens, sup- 
pressor T cells that inhibit systemic 
IgG, IgM, IgE, and cell-mediated im- 
mune responses have been described. 
These suppressor T cells have been 
identified within GALT for the first 2 
or 3 days following mucosal stimula- 
tion with antigen. Thereafter, they 
leave GALT and can be found in the 
spleen and other systemic sites (10). 
Teleologically, there would be an ad- 
vantage in preventing the potentially 
damaging systemic IgG response to the 
many harmless antigens present along 
the gastrointestinal tract. If such vig- 
orous systemic immunity resulted in all 
luminal antigens, it would set the stage 
for Arthus-type reactions to trivial an- 
tigen stimulation along the delicate in- 
testinal epithelium. 
Lymphocyte Trafficking in 
the Gut 
Following their stimulation in 
GALT, antigen-specific IgA precursor 
B lymphocytes travel to the mesenteric 
lymph nodes, thoracic duct, mature 
further in the spleen, and eventually 
migrate back to mucosal surfaces (1). 
In addition to the location where initial 
antigenic stimulation occurred, these 
antigen-specific IgA B lymphocytes 
(and preplasma cells) populate other 
mucosal sites around the body: mam- 
mary glands, lacrimal glands, salivary 
glands, and bronchial mucosal. This 
may serve to protect a variety of mu- 
cosal surfaces against antigens present 
in the environment. To a certain ex- 
tent, the presence of antigen at one 
particular surface can enhance the 
number of IgA-secreting plasma cells 
that select that site (13). 
The total time for the lymphocyte re- 
circulation following oral antigen stim- 
ulation is 4 to 6 days. In studies 
wherein the Peyer's patches are directly 
injected with antigen, an IgA specific 
response to the antigen can be seen 
within 2 to 3 days. This implies that 
the initial antigen processing event, 
from intestinal lumen through M cell, 
to antigen presenting cell, requires ap- 
proximately 2 days. 
Secretory IgA 
against Enteropathogens 
As secretory IgA lies at the portal of 
entry for enteropathogens, several 
model systems have been developed to 
determine the optimal means of pro- 
ducing a vigorous mucosal immune re- 
sponse to these agents. Further, recent 
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studies have indicated that the presence 
of secretory IgA to enteropathogens 
and/or their toxic products can inhibit 
the pathologic events. 
To follow the kinetics of the IgA re- 
sponse in intestinal secretions, our lab- 
oratory developed a chronically 
isolated, ileal loop model in rabbits. 
With proper daily care, these chroni- 
caily isolated, ileal loops can be main- 
tained for at least one month in 90% of 
the rabbits. Using this model system, 
we have followed the mucosal immune 
response to S. flexneri and other entero- 
pathogens. Following oral immuniza- 
tion with live or killed S. flexneri, a 
weak, primary IgA response is detected 
in secretions by 6 -8  days following 
oral stimulation. The response is 
stronger when a live vaccine is used 
than when the killed oral vaccine is 
given. The kinetics of the development 
of the response are the same for both, 
however. This model system was used 
to document the existence in intestinal 
secretions of a secretory IgA memory 
response after appropriate priming. For 
a mucosal memory response, animals 
were primed with 3 weekly oral doses 
of live S. flexneri, then left for 60 days, 
and rechallenged orally with the same 
strain of Shigella. A vigorous secre- 
tory IgA response could be detected in 
intestinal secretions within two days 
following rechallenge (7). In addition 
to accelerated kinetics, the IgA activity 
attained was significantly stronger than 
that achieved by the primary stimula- 
tion. Interestingly, heat-killed Shigella 
given orally were unable to prime for a 
mucosal memory response regardless of 
the dosage given. 
Since it was possible that the inva- 
sive capabilities of the Shigella used in 
our initial studies were responsible for 
the IgA memory response obtained in 
the intestinal secretions, we used 2 
noninvasive strains of Shigella in sub- 
sequent experiments. One strain, S. 
flexneri 2457-0, was noninvasive by the 
Sereny test; however, it contained a 
140 megadalton virulence plasmid, 
which is found in pathogenic strains 
and thought to be associated with inva- 
sion. The second strain, M4243A l, has 
been cured of this virulence plasmid 
and shows no invasive capabilities by 
Sereny test or rabbit ileal loop model. 
Both strains were able to prime rabbits 
for a secretory IgA memory response 
that was as strong as had been seen 
previously with the virulent strains (8). 
This indicates that even noninvasive, 
live bacteria are processed by the mu- 
cosal immune system to prime the an- 
imal for a mucosal memory response. 
Such findings offer considerable 
promise for future mucosal vaccine re- 
search. Whether the secretory IgA 
produced against these bacteria is pro- 
tective has not been determined. In 
similar studies in our laboratory using 
cholera toxin and Shiga's toxin, how- 
ever, the secretory IgA produced was 
able to interfere with the pathologic ef- 
fects of those molecules. 
The same kinetics of the secretory 
IgA response have been found by sev- 
eral groups using different model 
systems. For instance, Clements and 
colleagues gave heat-labile Escherichia 
coli enterotoxin B subunit (nontoxic) 
orally to BALB/c mice. They collected 
the intestinal contents at time of sacri- 
fice and were able to determine that the 
purified IgA anti-B subunit was capable 
of neutralizing the biologic activities of 
the E. coli toxin in vitro. Further, 
they were able to determine that either 
oral or intraperitoneal dose of antigen 
could boost, or hyperstimulate the mu- 
cosal IgA response (3). Although they 
were only able to obtain one datum 
point per mouse, the use of inbred mice 
for these studies is a considerable ad- 
vantage over the rabbit model for un- 
derstanding the immunogenetics 
involved in the response. The parallel 
to the rabbit system is, however, 
striking. For instance, in our most re- 
cent studies, we have found that a 
combination of parenteral and oral 
doses of antigen will give a boost to the 
primary IgA response to ShigeUa. 
Functional Significance of 
Secretory IgA Response 
to Enteropathogens 
Although systemic humoral immu- 
nity, mainly IgG, affords protection via 
opsonization for phagocytosis, activa- 
tion of complement, and, perhaps, 
antibody-dependent cell-mediated 
cytotoxicity, IgA does not seem to be 
proficient at these tasks. Since some 
enteropathogens, such as S. flexneri, 
often result in ulceration with elicitation 
of a polymorphonuclear leukocyte in- 
flammatory response, it has been im- 
portant to determine whether secretory 
IgA directed against these enteropatho- 
gens plays a role in opsonizing for 
phagocytosis. There has been some 
work that suggests that IgA may en- 
hance phagocytosis. For instance, 
Edebo and associates coated Salmonella 
typhimurim with dinitrophenol (DNP). 
They reacted these DNP-coated bacteria 
with a mouse myeloma protein (MOPC 
315), a monomeric IgA directed against 
DNP (4). Although this IgA was able 
to enhance the interaction of the bac- 
teria with phagocytic cells, the IgA 
monoclonal was much less efficient at 
this process than was IgG. This is not 
the form of IgA that is usually present 
in intestinal secretions, however. In- 
deed, studies in which secretory IgA 
was used to study opsonization have 
found that it may inhibit the opsoniza- 
tion for phagocytosis (11). 
The most likely protective role for 
secretory IgA was suggested by Fubara 
and Freter 15 years ago. They hypoth- 
esized that secretory IgA would in- 
terfere with colonization or attachment 
of microorganisms to the surface epi- 
thelium (5). More recent studies using 
parasites and small toxins to stimulate 
mucosal immunity support Freter's in- 
sightful suggestion. For instance, 
studies in which Giardia trophozoites 
were given via an intraintestinal immu- 
nization route, demonstrated that secre- 
tory IgA is readily produced to these 
parasites. Further, secretory IgA bound 
to these parasites and was able to in- 
crease the clearance of these micro- 
organisms. Scanning electron 
microscopy detected IgA bound to the 
adhesive dishes of these parasites (9). 
Lastly, in recent studies using Shiga's 
bacillus toxin, our laboratory, working 
together with Brown, found that the 
IgA anti-Shiga toxin activity correlates 
significantly with the ability of intes- 
tinal secretions to neutralize the effects 
of Shiga's toxin on tissue culture cells. 
The secretory IgA system provides 
an effective defense along mucosal sur- 
faces to a wide variety of bacteria, 
virus, parasites, and toxins. When ap- 
propriately primed, the secretory IgA 
system will produce a strong memory 
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response. The antibody elicited will 
prevent binding of bacteria, parasites, 
and toxic molecules to the epithelial 
cell surfaces. Considerable future work 
is needed to better understand the op- 
timal means of immunization and to re- 
view the function of the secretory IgA 
molecules produced in dealing with en- 
teric infections. 
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The ability of phagocytic leukocytes 
to kill ingested microorganisms arises 
from two general mechanisms. One of 
these depends on the phagocyte's 
ability to assemble and activate a mul- 
ticomponent oxidase system that gen- 
erates superoxide anion (O2-) by 
oxidizing its substrate, NADPH. The 
resultant superoxide anions are con- 
verted to other reactive oxygen deriva- 
tives (RODs), whose precise chemical 
nature is influenced by the biochemical 
composition of the phagocyte. In 
normal human neutrophils (PMN), 
these secondary RODs include H202, 
hydroxyl radicals, hypochlorous acid, 
and chloramines (18), all of which are 
considerably more microbicidal than 
superoxide itself. In addition to under- 
going an oxidative attack by RODs, in- 
gested microbes are exposed to,  
antimicrobial constituents normally 
contained within the phagocyte's cyto- 
plasmic granules. 
This report will focus on defensins, 
a recently defined family of antimicro- 
bial peptides whose members appear to 
be important effectors of ROD-inde- 
pendent antimicrobial activity by PMN 
and certain macrophages. The activity 
spectrum of human and rabbit defensins 
encompassess both gram-positive and 
gram-negative bacteria (3, 13), fungi 
(3, 14), certain viruses (I ,  9), and even 
tumor cells (11). This review will de- 
scribe both our recent studies with 
human PMN defensins and certain ear- 
lier studies that we performed on ho- 
mologous peptides from rabbit 
leukocytes. Readers seeking informa- 
tion about other ROD-independent an- 
timicrobial components of PMN, such 
as B/PI or cathepsin G, may consult 
other recent reviews (2, 17). 
134 0197-1859/87"$0.0o + 02.20 © 1987 Elsevier Science Publishing Co., Inc. Clirfical Immunology Newsletter 8:9.1987 
